Merck won two R & D 100 innovation awards in 2018

November 28, 2018 / AP / -- Merck, a leading technology company, today announced that it has won two R & D 100 awards The annual R & D 100 award aims to recognize the 100 most innovative breakthrough technologies in the previous year Merck's bioreliance ® virus and gene therapy test service and proxy CRISPR technology won the award at the 56th award Merck has won nine R & D 100 awards in the past six years "We are honored to receive two R & D 100 awards," said udit batra, a member of Merck's executive board and chief executive of life sciences The first award recognizes our ongoing efforts in gene therapy by rapidly developing and implementing bioreliance ® virus and gene therapy trials to make gene therapy more accessible to patients in need The second award recognizes our leadership in the gene editing market thanks to our long-term focus on CRISPR technology development I'm very proud of our team, who are working every day to solve the biggest challenges in life science " Merck's bioreliance ® virus and gene therapy trial service won the R & D 100 analysis / testing award Bioreliance ® virus and gene therapy test service is a test platform that can release virus and gene therapy vectors in time, reduce test time by nearly half, and provide accurate and reliable results Merck has developed tests specifically for the characterization, purity, efficacy, safety and release testing of viral gene therapy products Merck's proxy CRISPR technology won the special market breakthrough product award The market breakthrough awards are designed to recognize technologies that have the potential to become innovators that not only change existing technologies, but also change industry development Proxy CRISPR is a new genome editing tool for improving the expression of other newly discovered CRISPR proteins This technology opens up the DNA helix, allowing researchers to make precise sequence changes in previously inaccessible regions of the genome, thus making CRISPR more efficient, flexible and specific Merck's proxy CRISPR provides a quick and easy way to improve usability without having to work hard to recombine the native CRISPR protein The R & D 100 award is one of the most prestigious innovation awards in recognition of pioneers in research and development Merck is a leading technology company, focusing on three major areas of health care, life science and high-performance materials Around 53000 employees around the world serve Merck Merck is committed to creating a sustainable and pleasant lifestyle and improving the daily lives of millions of people The fields involved include promoting gene editing technology, finding unique methods to treat the most difficult diseases, and realizing intelligent devices In 2017, Merck's total sales in 66 countries reached 15.3 billion euros Scientific exploration and responsible management are the key to Merck's technology and scientific progress This is also the reason why Merck has been developing since it was founded in 1668 The Merck family still holds a majority stake in the publicly traded Merck group Merck owns the name and brand of "Merck" all over the world, with the only exceptions being in the United States and Canada, where Merck uses EMD Serono to run its health care business, millipore Sigma to run its life science business, and EMD performance materials business.